Login to Your Account

M&A Deals

Investors Still Waiting on a ‘Land Grab’ for Biotechs

By Peter Winter

Monday, October 14, 2013

Mergers and acquisitions have always been a regular staple in the biotech industry. However, the speculation that a “land grab” for attractive and product rich biotechnology companies would gather steam in the third quarter has not panned out so far. In fact, the list of companies that investors are betting on that will be take-out targets remains longer than the actual number of consummated deals.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription